M Holdings Securities Inc. Acquires 6,726 Shares of McKesson Corporation $MCK

M Holdings Securities Inc. bought a new position in shares of McKesson Corporation (NYSE:MCK) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 6,726 shares of the company’s stock, valued at approximately $5,743,000.

Several other large investors have also recently bought and sold shares of MCK. Brighton Jones LLC grew its position in McKesson by 22.5% during the third quarter. Brighton Jones LLC now owns 3,902 shares of the company’s stock worth $3,332,000 after buying an additional 716 shares in the last quarter. American State Bank Iowa increased its stake in McKesson by 7.8% during the third quarter. American State Bank Iowa now owns 428 shares of the company’s stock valued at $365,000 after acquiring an additional 31 shares during the period. Ethic Inc. raised its holdings in McKesson by 17.3% in the 3rd quarter. Ethic Inc. now owns 8,190 shares of the company’s stock valued at $6,993,000 after acquiring an additional 1,208 shares in the last quarter. Pictet Asset Management Holding SA raised its holdings in McKesson by 2.6% in the 3rd quarter. Pictet Asset Management Holding SA now owns 98,944 shares of the company’s stock valued at $84,497,000 after acquiring an additional 2,550 shares in the last quarter. Finally, Parallel Advisors LLC lifted its position in shares of McKesson by 1.5% in the 3rd quarter. Parallel Advisors LLC now owns 3,048 shares of the company’s stock worth $2,603,000 after acquiring an additional 44 shares during the period. 85.07% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting McKesson

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: McKesson beat fiscal Q2 2027 estimates, reporting adjusted EPS of $11.68 and revenue of about $111 billion, up roughly 7.5% year over year. The company also raised its fiscal 2027 adjusted EPS outlook to $45.60–$46.40, supported by specialty-drug demand, higher prescription volumes and operating gains. MCK Q2 Earnings Beat Estimates on Specialty Growth, Outlook Raised
• Positive Sentiment: Analyst sentiment has strengthened: UBS raised its price target to $1,250 and maintained a Buy rating, while TD Cowen and Leerink Partners lifted targets to $1,200. Separately, Zacks upgraded MCK to Rank #2 (Buy), citing improving earnings prospects. Zacks upgrades McKesson to Buy
• Neutral Sentiment: EVP Francisco Fraga sold 650 shares under a pre-arranged Rule 10b5-1 plan and retained 4,414 shares. The filing does not explain the purpose of this latest sale; an earlier sale was described as covering tax withholding on vested equity awards. SEC filing
• Negative Sentiment: RBC raised its price target but kept a Sector Perform rating and set a $965 target, below the recent share price. That more cautious view may temper enthusiasm after MCK’s strong run. RBC comments on McKesson’s execution

McKesson Stock Down 0.0%

NYSE MCK opened at $1,060.79 on Monday. The stock has a market cap of $122.48 billion, a P/E ratio of 27.28, a PEG ratio of 1.97 and a beta of 0.27. The company’s 50-day simple moving average is $938.13 and its 200 day simple moving average is $868.12. McKesson Corporation has a twelve month low of $723.68 and a twelve month high of $1,121.50.

McKesson (NYSE:MCK) last announced its quarterly earnings results on Wednesday, November 4th. The company reported $11.68 EPS for the quarter, topping analysts’ consensus estimates of $10.72 by $0.96. The firm had revenue of $110.96 billion during the quarter, compared to analysts’ expectations of $109.90 billion. McKesson had a net margin of 1.12% and a negative return on equity of 202.94%. The company’s revenue for the quarter was up 7.5% compared to the same quarter last year. During the same quarter last year, the company earned $9.86 earnings per share. Research analysts anticipate that McKesson Corporation will post 46.21 earnings per share for the current year.

McKesson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, January 4th. Stockholders of record on Tuesday, December 1st will be issued a $0.94 dividend. The ex-dividend date of this dividend is Tuesday, December 1st. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.4%. McKesson’s dividend payout ratio is presently 9.67%.

Insider Buying and Selling

In related news, CAO Napoleon B. Rutledge, Jr. sold 111 shares of the business’s stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $891.45, for a total value of $98,950.95. Following the sale, the chief accounting officer owned 521 shares of the company’s stock, valued at $464,445.45. The trade was a 17.56% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Francisco Fraga sold 800 shares of the company’s stock in a transaction on Thursday, October 15th. The shares were sold at an average price of $995.80, for a total value of $796,640.00. Following the completion of the sale, the executive vice president owned 5,423 shares in the company, valued at $5,400,223.40. This trade represents a 12.86% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 2,161 shares of company stock valued at $2,242,515. 0.06% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the company. Evercore reissued an “outperform” rating and set a $950.00 price objective (down from $1,000.00) on shares of McKesson in a report on Thursday, August 6th. Wells Fargo & Company boosted their price objective on McKesson from $812.00 to $933.00 and gave the company an “equal weight” rating in a research report on Tuesday, August 11th. Weiss Ratings upgraded McKesson from a “buy (b-)” rating to a “buy (b)” rating in a research note on Friday, September 4th. Bank of America raised their target price on McKesson from $950.00 to $1,050.00 in a research report on Thursday, August 6th. Finally, Barclays lifted their price target on shares of McKesson from $925.00 to $1,000.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 19th. Fifteen equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $1,026.18.

McKesson Company Profile

McKesson Corporation is a healthcare services and information technology company that distributes pharmaceuticals and other medical products. Its customers include pharmacies, hospitals, health systems, clinics and other healthcare providers.

The company also provides medical-surgical supplies and technology and services that support pharmacy operations, prescription management and care delivery. Its offerings include specialized support for oncology and other areas of care.

Founded in 1833, McKesson serves customers primarily in the United States and Canada.